Stephens L C, Haire W D, Schmit-Pokorny K, Kessinger A, Kotulak G
Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-1210.
Bone Marrow Transplant. 1993 Jan;11(1):51-4.
Granulocyte-macrophage colony stimulating factor (GM-CSF) has been used to augment circulating hemopoietic stem cells in the peripheral blood and promote efficient peripheral stem cell (PSC) collection. Anecdotal reports indicate that GM-CSF may contribute to apheresis catheter dysfunction during PSC collection. We prospectively evaluated thrombotic occlusion rate of inferior vena cava (IVC) catheters following introduction of GM-CSF compared with a control group who underwent PSC collection prior to introduction of GM-CSF. Both groups were given aspirin (325 mg daily). The active treatment group was given GM-CSF (starting dose 250 micrograms/m2/day) as continuous infusion via the IVC catheter. The rate of thrombotically occluded catheters increased from 1/29 (3%) to 20/37 (54%) (p < 0.0001). Thrombi developing during GM-CSF therapy were unusual as 25/36 (69%) occlusions cleared with mechanical clot aspiration and did not require lytic agents.
粒细胞巨噬细胞集落刺激因子(GM-CSF)已被用于增加外周血中循环造血干细胞数量,并促进外周干细胞(PSC)的有效采集。轶事报道表明,GM-CSF可能导致PSC采集过程中血液成分单采导管功能障碍。我们前瞻性评估了与在引入GM-CSF之前进行PSC采集的对照组相比,引入GM-CSF后下腔静脉(IVC)导管的血栓闭塞率。两组均给予阿司匹林(每日325毫克)。活性治疗组通过IVC导管持续输注GM-CSF(起始剂量250微克/平方米/天)。血栓闭塞导管的发生率从1/29(3%)增加到20/37(54%)(p<0.0001)。GM-CSF治疗期间形成的血栓不同寻常,因为36例中有25例(69%)的闭塞通过机械性血栓抽吸得以清除,无需使用溶栓剂。